ViaNautis Bio announces $25m Series A financing to drive the next generation of genetic nanomedicines
ViaNautis’s proprietary drug delivery platform, polyNaut, is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need